These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 33850556)

  • 1. Diclofenac impairs the proliferation and glucose metabolism of triple-negative breast cancer cells by targeting the c-Myc pathway.
    Yang L; Li J; Li Y; Zhou Y; Wang Z; Zhang D; Liu J; Zhang X
    Exp Ther Med; 2021 Jun; 21(6):584. PubMed ID: 33850556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-Bromopyruvic acid regulates glucose metabolism by targeting the c-Myc/TXNIP axis and induces mitochondria-mediated apoptosis in TNBC cells.
    Li J; Pan J; Liu Y; Luo X; Yang C; Xiao W; Li Q; Yang L; Zhang X
    Exp Ther Med; 2022 Aug; 24(2):520. PubMed ID: 35837063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-Bromopyruvate Inhibits the Growth and Glucose Metabolism of TNBC Xenografts in Nude Mice by Targeting c-Myc.
    Pan JM; Li JC; Yang C; Xiao WF; Li QS; Luo XH; Zhang XD
    Anticancer Agents Med Chem; 2023; 23(12):1421-1428. PubMed ID: 37038711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New aspects of an old drug--diclofenac targets MYC and glucose metabolism in tumor cells.
    Gottfried E; Lang SA; Renner K; Bosserhoff A; Gronwald W; Rehli M; Einhell S; Gedig I; Singer K; Seilbeck A; Mackensen A; Grauer O; Hau P; Dettmer K; Andreesen R; Oefner PJ; Kreutz M
    PLoS One; 2013; 8(7):e66987. PubMed ID: 23874405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physciosporin suppresses mitochondrial respiration, aerobic glycolysis, and tumorigenesis in breast cancer.
    Taş İ; Varlı M; Son Y; Han J; Kwak D; Yang Y; Zhou R; Gamage CDB; Pulat S; Park SY; Yu YH; Moon KS; Lee KH; Ha HH; Hur JS; Kim H
    Phytomedicine; 2021 Oct; 91():153674. PubMed ID: 34333327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.
    Shen L; O'Shea JM; Kaadige MR; Cunha S; Wilde BR; Cohen AL; Welm AL; Ayer DE
    Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5425-30. PubMed ID: 25870263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Methoxy-1,4-Naphthoquinone (MNQ) Inhibits Glucose Uptake and Lactate Production in Triple-Negative Breast Cancer Cells.
    Daud SM; Yaacob NS; Fauzi AN
    Asian Pac J Cancer Prev; 2021 Feb; 22(S1):59-65. PubMed ID: 33576213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer.
    Wu Q; Ba-Alawi W; Deblois G; Cruickshank J; Duan S; Lima-Fernandes E; Haight J; Tonekaboni SAM; Fortier AM; Kuasne H; McKee TD; Mahmoud H; Kushida M; Cameron S; Dogan-Artun N; Chen W; Nie Y; Zhang LX; Vellanki RN; Zhou S; Prinos P; Wouters BG; Dirks PB; Done SJ; Park M; Cescon DW; Haibe-Kains B; Lupien M; Arrowsmith CH
    Nat Commun; 2020 Aug; 11(1):4205. PubMed ID: 32826891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Let-7a-5p inhibits triple-negative breast tumor growth and metastasis through GLUT12-mediated warburg effect.
    Shi Y; Zhang Y; Ran F; Liu J; Lin J; Hao X; Ding L; Ye Q
    Cancer Lett; 2020 Dec; 495():53-65. PubMed ID: 32946964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
    Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
    Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
    Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
    Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of OLR1 weakens glycolytic metabolism to repress colon cancer cell proliferation and chemoresistance by downregulating SULT2B1 via c-MYC.
    Zhao T; Li Y; Shen K; Wang Q; Zhang J
    Cell Death Dis; 2021 Dec; 13(1):4. PubMed ID: 34921134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative administration of ketorolac averts morphine-induced angiogenesis and metastasis in triple-negative breast cancer.
    Liu Z; Cheng S; Fu G; Ji F; Wang C; Cao M
    Life Sci; 2020 Jun; 251():117604. PubMed ID: 32243929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
    Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
    Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
    Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
    Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
    Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CircXPO6 promotes breast cancer progression through competitively inhibiting the ubiquitination degradation of c-Myc.
    Xu A; Li X; Cai Q; Yang C; Yang M; Gao H; Cheng M; Chen X; Ji F; Tang H; Wang K
    Mol Cell Biochem; 2024 Aug; ():. PubMed ID: 39179754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New substituted quinoxalines inhibit triple-negative breast cancer by specifically downregulating the c-MYC transcription.
    Hu MH; Wu TY; Huang Q; Jin G
    Nucleic Acids Res; 2019 Nov; 47(20):10529-10542. PubMed ID: 31584090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.